{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Bliss GVS Pharma Gains 5.20%: Key Milestones and Market Dynamics This Week
Bliss GVS Pharma Ltd delivered a robust weekly performance, rising 5.20% from Rs.262.60 to Rs.276.25 between 27 April and 30 April 2026, comfortably outperforming the Sensex’s modest 0.47% gain over the same period. The stock’s rally was fuelled by significant milestones including a new 52-week high and an all-time high price, underscoring strong investor interest and positive technical momentum amid a mixed broader market backdrop.
Bliss GVS Pharma Ltd is Rated Hold
Bliss GVS Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 12 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Broad-Based Technical Strength Lifts Bliss GVS Pharma Ltd to 52-Week High of Rs 280.2
With a remarkable 122.33% gain over the past year, Bliss GVS Pharma Ltd surged to a fresh 52-week high of Rs 280.2 on 28 Apr 2026, outpacing the Sensex which declined by 3.62% during the same period. This milestone caps a sustained rally fuelled by strong technical momentum and a series of bullish signals across multiple timeframes.
Bliss GVS Pharma Ltd Hits All-Time High of Rs 278.2 as Momentum Builds Across Timeframes
Bliss GVS Pharma Ltd has reached a significant milestone by touching an all-time high price of Rs.278.2 on 28 April 2026, marking a remarkable phase in the company’s market performance within the Pharmaceuticals & Biotechnology sector.
Bliss GVS Pharma Gains 1.65%: 4 Key Factors Driving the Week’s Momentum
Bliss GVS Pharma Ltd recorded a modest weekly gain of 1.65% to close at Rs.262.60 on 24 April 2026, outperforming the Sensex which declined by 1.31% over the same period. The stock demonstrated strong intraday rallies midweek, hitting new 52-week and all-time highs, supported by bullish technical indicators and an upgrade in its Mojo Grade to ‘Hold’. Despite a late-week pullback, the stock’s resilience amid a weakening broader market highlights its sustained momentum in the Pharmaceuticals & Biotechnology sector.
Broad-Based Technical Strength Lifts Bliss GVS Pharma Ltd to 52-Week High of Rs 277.7
With a remarkable 120.83% gain over the past year, Bliss GVS Pharma Ltd surged to a fresh 52-week high of Rs 277.7 on 23 Apr 2026, showcasing a sustained momentum that outpaces the broader Sensex, which declined by 2.58% over the same period.
Strong Momentum Meets Stretched Valuations as Bliss GVS Pharma Ltd Reaches All-Time High
Bliss GVS Pharma Ltd has reached a significant milestone by hitting its all-time high price of Rs. 277.45 on 23 April 2026, marking a remarkable phase in the company’s market journey within the Pharmaceuticals & Biotechnology sector.
Broad-Based Technical Strength Lifts Bliss GVS Pharma Ltd to 52-Week High of Rs 272.95
From a 52-week low of Rs 105.05 to a new peak of Rs 272.95, Bliss GVS Pharma Ltd has more than doubled in value over the past year, delivering a remarkable 119.3% return. This surge comes amid a backdrop of mixed market conditions, with the Sensex down 0.73% today but up nearly 7% over the last three weeks, highlighting the stock’s standout momentum in the Pharmaceuticals & Biotechnology sector.
Bliss GVS Pharma Ltd Hits All-Time High of Rs 271.65 as Momentum Builds Across Timeframes
Bliss GVS Pharma Ltd has reached a new all-time high price of Rs.271.65 on 22 April 2026, reflecting a remarkable performance in the Pharmaceuticals & Biotechnology sector. This milestone underscores the company’s sustained upward trajectory and robust market presence.
Bliss GVS Pharma Ltd is Rated Hold
Bliss GVS Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 12 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Bliss GVS Pharma Ltd’s Mixed Week: -0.12% Price Change Amidst New Highs and Market Gains
Bliss GVS Pharma Ltd experienced a mixed week with its share price closing marginally lower by 0.12% at Rs.258.35, despite hitting a new all-time high of Rs.267.15 on 15 April 2026. The stock’s performance contrasted with the broader Sensex, which advanced 2.33% over the same period, reflecting sector-specific volatility amid strong technical momentum and notable trading activity.
Broad-Based Technical Strength Lifts Bliss GVS Pharma Ltd to 52-Week High of Rs 267.15
Surging past its previous peak, Bliss GVS Pharma Ltd touched a new 52-week high of Rs 267.15 on 15 Apr 2026, marking a remarkable 110.64% gain over the past year. This milestone comes amid a sustained rally driven by a confluence of bullish technical indicators and consistent price momentum.
Bliss GVS Pharma Ltd Hits All-Time High of Rs 267.15 as Momentum Builds Across Timeframes
Bliss GVS Pharma Ltd has reached a new all-time high price of Rs.267.15 on 15 Apr 2026, reflecting a remarkable phase of growth and resilience in the Pharmaceuticals & Biotechnology sector. This milestone underscores the company’s sustained performance and positive market momentum over recent periods.
Bliss GVS Pharma Gains 9.14%: 7 Key Factors Driving the Surge
Bliss GVS Pharma Ltd delivered a strong weekly performance, rising 9.14% from Rs.237.00 on 6 April to Rs.258.65 on 10 April 2026, comfortably outperforming the Sensex’s 5.34% gain over the same period. The stock hit multiple new 52-week and all-time highs during the week, reflecting robust buying interest amid a mixed broader market environment. Key valuation shifts, technical signals, and financial metrics contributed to the stock’s momentum, making this week a notable chapter in its ongoing market journey.
Bliss GVS Pharma Ltd is Rated Hold by MarketsMOJO
Bliss GVS Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 12 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 April 2026, providing investors with an up-to-date perspective on its performance and outlook.
Broad-Based Technical Strength Lifts Bliss GVS Pharma Ltd to 52-Week High of Rs 261.1
From a 52-week low of Rs 105.05 to a fresh peak of Rs 261.1, Bliss GVS Pharma Ltd has more than doubled in value over the past year, showcasing a remarkable 123.31% return that far outpaces the Sensex’s modest 4.40% gain. This milestone was reached on 9 Apr 2026, driven by a confluence of strong technical signals and sustained price momentum.
From Steady Gains to Record Close: Bliss GVS Pharma Ltd Hits All-Time High at Rs 261.1
Extending its recent rally, Bliss GVS Pharma Ltd touched a fresh all-time high of Rs 261.1 on 09 Apr 2026, marking a significant milestone in its price journey. This surge comes amid strong outperformance against the broader market and a backdrop of bullish technical signals.
Bliss GVS Pharma Ltd Valuation Shifts Signal Changing Market Perception
Bliss GVS Pharma Ltd has witnessed a notable shift in its valuation parameters, moving from fair to expensive territory, reflecting a changing price attractiveness for investors. With a current P/E ratio of 24.18 and a P/BV of 2.36, the pharmaceutical company’s stock valuation now demands closer scrutiny against its historical averages and peer group benchmarks.
Broad-Based Technical Strength Lifts Bliss GVS Pharma Ltd to 52-Week High of Rs 250.95
Surging past its previous peaks, Bliss GVS Pharma Ltd touched a new 52-week high of Rs 250.95 on 8 Apr 2026, marking a remarkable 105.26% gain over the past year. This milestone comes amid a strong technical backdrop and a market environment where the Sensex itself is trading with mixed signals.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
